Fig 1: Overexpression of CYP1A2 can partially rescue the effect of miR-23b-3p overexpression on hBMSCs. (a) qRT-PCR to detect the transfection efficiency of CYP1A2 overexpression plasmid; (b) CCK8 assay to detect cell proliferation; (c) ALP staining (200×); (d) ARS staining (200×). Compared with the NC group, # P < 0.05; compared with the miR-NC group, * P < 0.05; compared with the miR-23b-3p mimic + NC group, ^ P < 0.05. ALP: alkaline phosphatase; ARS: alizarin red staining; hBMSCs: human bone marrow mesenchymal stem cells.
Fig 2: CYP1A2 is a target of miR-23b-3p. (a) RNA22 database predicted that CYP1A2 and miR-23b-3p had a binding site; (b) dual luciferase reporter assay indicated that there was a targeting relationship between CYP1A2 and miR-23b-3p; (c) String database predicted that CYP1A2 was associated with risk genes for SNFH; (d) CYP1A2 expression in SNFH tissues; (e) CYP1A2 expression in hBMSCs; (f) CYP1A2 and miR-23b-3p were negatively correlated. Compared with the control group, ^ P < 0.05. SNFH: steroid-induced necrosis of femoral head; hBMSCs: human bone marrow mesenchymal stem cells.
Supplier Page from Abcam for Anti-Cytochrome P450 1A2 antibody [EPR6138(2)]